Journal article

Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals

Gail V Matthews, Rachel J Ali, Anchalee Avihingsanon, Janaki Amin, Rachel Hammond, Scott Bowden, Sharon R Lewin, Joe Sasadeusz, Margaret Littlejohn, Stephen L Locarnini, Kiat Ruxrungtham, Gregory J Dore



Awarded by National Research University Project of CHE

Funding Acknowledgements

Gilead sciences provided unrestricted grant support to complete quantitative testing for this study. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.The authors have read the journals policy and declare the following conflicts. Matthews GV: Grant funding: Gilead, MSD, Speakers bureau: Gilead, Roche, MSD, BMS, Janssen, Travel support: Janssen, MSD. Ali RJ: None. Avihingsanon A: None. Lewin SR: Grant funding: Gilead and Merck; Paid consultant and speaker: Gilead, Viiv Healthcare; Advisory Board: Gilead and Merck. Sasadeusz J: Gilead: research funding, meeting sponsorship, Merck: research funding, meeting sponsorship, BMS: research funding, Roche: research funding, paid speaker, advisory board. Hammond R: None. Bowden S: Speaker with honorarium for Gilead, Bristol-Myers Squibb, Roche and Merck. Littlejohn M: None. Locarnini S: Royalties - "Melbourne Health; Receipt of Intellectual Property Rights/Patent Holder -" Melbourne Health; Consulting Fees (eg. Advisory Boards) - Evivar Pty Ltd, Gilead, Bristol-Myers Squibb; Fees for Non-CME Services Received Directly from a Commercial Interest or their Agent -Bristol-Myers Squibb, Merck Sharpe and Dohme Pty Ltd. Ruxrungtham K has been awarded Senior Researcher Scholar, Thai Research Fund; The National Research University Project of CHE (HR1161A), Ministry of Education; and the Professional Research Team Strengthening Fund, from the National Science and Technology Development Agency (NSTDA), BIOTEC, Ministry of Science and Technology; Thailand. He has also served as a consultant for Merck, and Tibotec. He has been a speaker with honorarium for Bristol-Myers Squibb, Merck, Roche, Jensen-Cilag, GlaxoSmithKline, and GPO. Dore GJ: Board membership: Roche, Merck, Janssen, Gilead, BMS; Honoraria: Roche, Merck, Janssen, Gilead, BMS; Research grants: Roche, Merck, Janssen, Gilead, BMS; Scholarship: Roche, Merck, Janssen. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.